Salivary Gland Acinic Cell Carcinoma
Associated Genetic Biomarkers
NCI Definition: A carcinoma of the salivary gland characterized by serous acinar cell differentiation. The vast majority of cases occur in the parotid gland. It usually presents as a slowly enlarging mass. A minority of patients experience pain. It may recur or metastasize. Multiple recurrences and metastasis to cervical lymph nodes are usually associated with a poor prognosis. 
Salivary gland acinic cell carcinomas most frequently harbor alterations in CDKN2A, CDKN2B, SETD2, PIK3CA, and FBXW7 .
CDKN2A Loss, CDKN2B Loss, SETD2 Mutation, PIK3CA Mutation, and TP53 c.217-c.1178 Missense are the most common alterations in salivary gland acinic cell carcinoma .
There are 2 clinical trials for salivary gland acinic cell carcinoma, of which 2 are open and 0 are completed or closed. Of the trials that contain salivary gland acinic cell carcinoma as an inclusion criterion, 2 are phase 2 (2 open).
ERBB2 and HER2 are the most frequent gene inclusion criteria for salivary gland acinic cell carcinoma clinical trials .
Nanoparticle-based paclitaxel suspension, cisplatin, and trastuzumab are the most common interventions in salivary gland acinic cell carcinoma clinical trials.
Significant Genes in Salivary Gland Acinic Cell Carcinoma
ERBB2 is altered in 2.86% of salivary gland acinic cell carcinoma patients .
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for salivary gland acinic cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and salivary gland acinic cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.